メインコンテンツに移動
ホーム

Dedicated to discovery

  • ELGAについて
    • ELGAについて
    • 採用情報
    • イベント
  • サポート
    • ラボのプランニング
    • 製品を登録
    • Register Your Product (USA & Canada Only)
  • お問い合わせ
  • U.S.A.
  • U.K.
  • Deutschland
  • España
  • France
  • Italia
  • Brasil
  • 中国
ホーム
  • 製品
    • PURELAB
      • PURELAB® Quest
      • PURELAB® Pharma Compliance
      • PURELAB® Chorus 1 Complete
      • PURELAB® Chorus 1
      • PURELAB® Chorus 2
      • PURELAB® Chorus 2 +
      • PURELAB® Chorus 3
      • PURELAB® flex 1
      • PURELAB® flex 2
      • PURELAB® flex 3
      • PURELAB® flex 4
      • PURELAB® flex 5
    • CENTRA
      • CENTRA® R60/120
      • CENTRA® R200
      • CENTRA® RDS
    • MEDICA
      • MEDICA® 7/15
      • MEDICA® Pro-R & Pro-RE
      • MEDICA® R200
      • MEDICA® EDI 15/30
      • MEDICA® Pro-LPS
      • MEDICA® Pro EDI 60/120
      • MEDICA® BIOX
      • Hubgrade
    • BIOPURE
      • BIOPURE® 300/600
    • PURENERGY 30
    • ELGA全製品ライン
  • 用途
    • ガスクロマトグラフィー
    • ラボ用水の一般要件
    • 免疫組織染色
    • 分光測光法
    • 原子分光学
    • 微生物学的分析
    • 液体クロマトグラフィー
    • 細胞培養
    • 臨床生化学
    • 質量分析
    • 遺伝学
    • 電気化学
  • 純水製造技術
    • PureSure
    • ろ過
    • イオン交換
    • 活性炭
    • 紫外線
    • 逆浸透(RO)
    • 電気脱イオン処理(EDI)
  • 水中の不純物
    • 微生物&細菌
    • 有機化合物
    • 溶存ガス
    • 無機化合物
    • 粒子状物質
  • 知識
    • ブログ
    • ケーススタディ
    • 超純水
    • ガイド&ホワイトペーパー
  • 認定パートナー
  • お問い合わせ
Home
  • お問い合わせ
  • 製品
    • PURELAB
      • PURELAB® Quest
      • PURELAB® Pharma Compliance
      • PURELAB® Chorus 1 Complete
      • PURELAB® Chorus 1
      • PURELAB® Chorus 2
      • PURELAB® Chorus 2 +
      • PURELAB® Chorus 3
      • PURELAB® flex 1
      • PURELAB® flex 2
      • PURELAB® flex 3
      • PURELAB® flex 4
      • PURELAB® flex 5
    • CENTRA
      • CENTRA® R60/120
      • CENTRA® R200
      • CENTRA® RDS
    • MEDICA
      • MEDICA® 7/15
      • MEDICA® Pro-R & Pro-RE
      • MEDICA® R200
      • MEDICA® EDI 15/30
      • MEDICA® Pro-LPS
      • MEDICA® Pro EDI 60/120
      • MEDICA® BIOX
      • Hubgrade
    • BIOPURE
      • BIOPURE® 300/600
    • PURENERGY 30
    • ELGA全製品ライン
  • 用途
    • ガスクロマトグラフィー
    • ラボ用水の一般要件
    • 免疫組織染色
    • 分光測光法
    • 原子分光学
    • 微生物学的分析
    • 液体クロマトグラフィー
    • 細胞培養
    • 臨床生化学
    • 質量分析
    • 遺伝学
    • 電気化学
  • 純水製造技術
    • PureSure
    • ろ過
    • イオン交換
    • 活性炭
    • 紫外線
    • 逆浸透(RO)
    • 電気脱イオン処理(EDI)
  • 水中の不純物
    • 微生物&細菌
    • 有機化合物
    • 溶存ガス
    • 無機化合物
    • 粒子状物質
  • 知識
    • ブログ
    • ケーススタディ
    • 超純水
    • ガイド&ホワイトペーパー
  • 認定パートナー
  • お問い合わせ
  • ELGAについて
    • ELGAについて
    • 採用情報
    • イベント
  • サポート
    • ラボのプランニング
    • 製品を登録
    • Register Your Product (USA & Canada Only)
  • お問い合わせ
  • U.S.A.
  • U.K.
  • Deutschland
  • España
  • France
  • Italia
  • Brasil
  • 中国
  • プライバシーポリシー
  • 利用規約
  • 世界的な法令順守
  • 特許
  • Trademarks
  • サイト管理者情報
  • ホーム
  • Could Faecal Testing Help Personalise Cancer Treatment?
Analytical Chemistry
Water Purity

Could Faecal Testing Help Personalise Cancer Treatment?

22 6月 2020
- by Dr Alison Halliday

Scientific Testing

A new study suggests that measuring short-chain fatty acids in the gut may offer a way to predict which cancer patients will benefit from immunotherapy.


Cancer therapies that target elements of the immune system – immunotherapies – are showing remarkable results for many patients. So-called ‘immune checkpoint inhibitors’ work by interfering with the mechanism that cancer cells use to evade destruction by the body’s immune system. Examples include nivolumab and pembrolizumab, which target a molecule on the surface of cells called PD–1.

Treating patients with immune checkpoint inhibitors can shrink tumours and improve survival rates, even for whom other therapies have failed. However, the response to these drugs varies widely from person to person – particularly for those with solid tumours.

If clinicians could predict who will benefit from cancer immunotherapies in advance, this would help spare many patients from the risk of unnecessary side effects. Defining the factors that can influence this variability in response will also improve our understanding of how these treatments work, identifying new opportunities for widening their effectiveness in the future.

The Gut Microbiome is a Suspect

Several studies have suggested that the population of microorganisms in our gut may influence the success of cancer immunotherapies. But the mechanisms behind this potential association remain unclear. One suspect are the short-chain fatty acids, which are the major end–products of gut microbiome–mediated metabolism. These molecules are thought to have wide-ranging effects on the whole body – including in modulating the immune response. 

In a new study, published in JAMA Network Open, scientists set out to explore whether short-chain fatty acids are associated with the clinical outcomes of patients with solid tumours treated with nivolumab or pembrolizumab.1

Evaluating Short-Chain Fatty Acid Concentrations

The researchers recruited 52 patients with solid tumours before they started treatment with nivolumab or pembrolizumab. They collected faecal and plasma samples and measured the concentrations of various short-chain fatty acids using ultra–high–performance liquid chromatography coupled with tandem mass spectrometry.

For these experiments, they used ultrapure water from an ELGA PURELAB® flex 5 water purification system, minimising the risk of introducing contaminants that may affect their results.

The scientists carried out scans to measure the size of the patients’ tumours at regular intervals over the study. They then carried out statistical analyses to evaluate if the levels of short-chain fatty acids were related to their response to treatment. They found that high concentrations of acetic acid, propionic acid, butyric acid and valeric acid in faecal samples – and isovaleric acid in plasma – were associated with patients living longer without their disease getting any worse. 

A Non–Invasive Test

This is the first study to identify a link between short-chain fatty acids and the effectiveness of PD–1 treatment for solid cancers. 

If these results are confirmed in larger studies, testing faecal samples from patients with solid tumours could offer a relatively simple way to predict who may benefit from nivolumab or pembrolizumab– paving the way to a more personalised approach to cancer immunotherapy in the future.

Why Choose ELGA LabWater?

ELGA’s expert engineers, chemists and scientists are at the forefront of technological innovation. We continue to introduce game-changing features to the laboratory water market.
 

Reference:

  1. Nomura M, et al. Association of Short–Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment with Nivolumab or Pembrolizumab in Patients with Solid Cancer Tumors. JAMA Network Open 2020;3(4):e202895


Dr Alison Halliday

After completing an undergraduate degree in Biochemistry & Genetics at Sheffield University, Alison was awarded a PhD in Human Molecular Genetics at the University of Newcastle. She carried out five years as a Senior Postdoctoral Research Fellow at UCL, investigating the genes involved in childhood obesity syndrome. Moving into science communications, she spent ten years at Cancer Research UK engaging the public about the charity’s work. She now specialises in writing about research across the life sciences, medicine and health.

risk whitepaper

When lives are at stake, there is no margin for error. Your clinical analyser must receive a constant and reliable supply of CLRW. 

Find out how to protect your test results

                   Click Here

 

  • Enquiry
  • 見積もりを取得
  • デモを予約する
  • 承認されたパートナーを見つける

Enquiry

At ELGA LabWater, we have exciting offers and news about our products and services that we hope you’d like to hear about. We will use your information to predict what you might be interested in. We will treat your data with respect and you can find the details in our Privacy Policy.

ELGA LabWater works with a network of Approved Partners. In order to answer your questions or enquiries, we may pass your contact details to an Approved Partner, who may contact you directly. 

I'd like to receive updates from ELGA LabWater & ELGA Approved Partners based on my details.

見積もりを取得

At ELGA LabWater, we have exciting offers and news about our products and services that we hope you’d like to hear about. We will use your information to predict what you might be interested in. We will treat your data with respect and you can find the details in our Privacy Policy.

ELGA LabWater works with a network of Approved Partners. In order to answer your questions or enquiries, we may pass your contact details to an Approved Partner, who may contact you directly. 

I'd like to receive updates from ELGA LabWater & ELGA Approved Partners based on my details.

デモを予約する

At ELGA LabWater, we have exciting offers and news about our products and services that we hope you’d like to hear about. We will use your information to predict what you might be interested in. We will treat your data with respect and you can find the details in our Privacy Policy.

ELGA LabWater works with a network of Approved Partners. In order to answer your questions or enquiries, we may pass your contact details to an Approved Partner, who may contact you directly. 

I'd like to receive updates from ELGA LabWater & ELGA Approved Partners based on my details.

Call us

Can't find what you are looking for?

Support Number
+44 (0)20 3567 7300
United Kingdom Sales
+44 (0)1628 879 704
United States of America Sales
+1 877-315-3542
France Sales
+33 1 40 83 65 00
China Sales
+86 400-616-8882

 

ELGA LabWater US Headquarters

Lane End Business Park
Lane End, High Wycombe
HP14 3BY
United Kingdom
電話: +44 (0) 203 567 7300
ファックス:+44 (0) 203 567 7205

ELGA LabWater本社

Lane End Business Park
Lane End, High Wycombe
HP14 3BY
United Kingdom
電話: +44 (0) 203 567 7300
ファックス:+44 (0) 203 567 7205

ケーススタディ

  • Abbott Diagnostics(アボットダイアグノスティクス)
  • DASA Medical Diagnostics(DASA医療診断)
  • NeoDIN Medical Institute(NeoDIN医療機関)
  • UHNS(University Hospital of North Staffordshire NHS Trust/北スタンフォードシャア大学病院)
  • Olsberg Vocational College(オルスバーグ専門学校)

リソース

  • 超純水について
  • ガイド&ホワイトペーパー
  • 純水製造技術
  • 用途
  • 水中の不純物

Blogs

  • Latest Blog
  • Water Purity - Different Types of Pure Water
  • What is Clinical Laboratory Reagent Water (CLSI)?
  • What is Total Organic Carbon (TOC)?

©VWS(UK)Ltd.はELGA LabWaterとして取引されています。2023-全著作権所有。
ELGAはVeoliaのグローバルなラボ用水のブランド名です。

  • プライバシーポリシー
  • 利用規約
  • 世界的な法令順守
  • 特許
  • Trademarks
  • サイト管理者情報
  • 言語
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Português
    • 日本語
    • 中文
  • 他のVeoliaサイト
    • Veolia
    • Veolia Foundation
    • Veolia Water Technologies
Elga Veolia
TOP

© 2017 ELGA Veolia